Search results for "Digestive System"

showing 10 items of 1747 documents

<i>BRAF</i> Mutation Testing in Lynch Syndrome Diagnostics: Performance and Efficiency According to Patient's Age

2019

Background: BRAF V600E mutations are reportedly associated with sporadic microsatellite-unstable (MSI) colorectal cancer (CRC), while rarely detected in CRCs of Lynch syndrome (LS) patients. Therefore, current international diagnostic guidelines recommend somatic BRAF mutation testing in MLH1-deficient MSI CRC patients to exclude LS. As sporadic BRAF- mutant MSI CRC is a disease of the elderly, while LS-associated CRC usually occurs at younger age, we hypothesized that the efficacy of BRAF testing in LS diagnostics may be age-dependent. Methods: We systematically compared the prevalence of BRAF mutations in LS-associated CRCs and MSI CRCs from population-based cohorts in different age group…

Oncologymedicine.medical_specialtyeducation.field_of_studyColorectal cancerbusiness.industryGenetic counselingPopulationCancerMicrosatellite instabilityDiseasemedicine.diseasedigestive system diseasesLynch syndromeInternal medicinemedicineMutation testingeducationbusinessneoplasmsSSRN Electronic Journal
researchProduct

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.

2009

Background: Cetuximab and panitumumab, mAbs targeting EGFR, are registered for metastatic colorectal carcinoma (mCRC) patients whose tumors express EGFR as determined by immunohistochemistry. However, this method is not predictive of treatment efficacy. KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene, encodes a small G-protein that functions downstream of EGFR-induced signalling. Objective/Methods: To examine KRAS mutations as predictive factors of response to anti-EGFR mAbs using recently published data. Results/conclusions: Several retrospective studies show that efficacy of these mAbs is confined to patients with wild type KRAS and genotyping of tumors should be consi…

Oncologymedicine.medical_specialtymedicine.drug_classColorectal cancerClinical BiochemistryPopulationCetuximabMonoclonal antibodymedicine.disease_causeAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsDrug DiscoverymedicinePanitumumabAnimalsHumansKRAScolorectal carcinomaeducationneoplasmsGenotypingPharmacologyeducation.field_of_studyClinical Trials as TopicCetuximabbusiness.industryPanitumumabAntibodies Monoclonalmedicine.diseasedigestive system diseasesErbB ReceptorsMutationCancer researchras ProteinsImmunohistochemistryKRASbusinessColorectal Neoplasmsmedicine.drugExpert opinion on biological therapy
researchProduct

(Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?

2005

Despite surgical R0 resections, patients with gastric cancer stage UICC II–III have a high risk of recurrence and metachronic metastases. Preliminary evidence exists that adjuvant chemotherapy or neoadjuvant chemo(radio)therapy protocols may improve the prognosis of these patients undergoing surgery of gastric cancer with curative intention. As for palliative regimens, 5-fluorouracil and cisplatin are integral components of such (neo)adjuvant strategies. Upcoming cytostatic agents, i.e. irinotecan, docetaxel, oxaliplatin, and oral fluoropyridines are currently under investigation in new multimodality treatment regimens and may further increase R0 resection rates and may prolong disease-free…

Oncologymedicine.medical_specialtymedicine.medical_treatmentGastric carcinomaStomach NeoplasmsInternal medicinemedicineHumansNeoplasm StagingCisplatinChemotherapybusiness.industryCarcinomaGastroenterologyCancerGeneral Medicinemedicine.diseaseNeoadjuvant Therapydigestive system diseasesOxaliplatinIrinotecanDocetaxelPractice Guidelines as TopicbusinessAdjuvantmedicine.drugDigestive Diseases
researchProduct

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

2021

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De…

Oncologysorafenib.Cancer Management and ResearchhepatocarcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssorafeniblenvatinibneoplasmsdigestive system diseasesRC254-282Original ResearchCancer Management and Research
researchProduct

Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells

2008

AIM: To explore the role of Bcl-x(L) and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treatment modalities. METHODS: Bcl-x(L) and Mcl-1 mRNA and protein expression were analyzed in CRC cell lines as well as human CRC tissue by Western blot, quantitative PCR and immunohistochemistry. Bcl-x(L) and Mcl-1 protein expression was knocked down or increased in CRC cell lines by applying specific siRNAs or expression plasmids, respectively. After modulation of protein expression, CRC cells were treated with chemotherapeutic agents, an antagonistic epidermal growth factor receptor (EGFR1) antibody, an EGFR1 tyrosine kinase inhibitor, …

Organoplatinum CompoundsCell SurvivalCellbcl-X ProteinAntineoplastic AgentsApoptosisBcl-xLAdenocarcinomaBiologyIrinotecanTNF-Related Apoptosis-Inducing LigandDownregulation and upregulationhemic and lymphatic diseasesCell Line TumormedicineHumansRNA Messengerfas ReceptorViability assayneoplasmsColorectal CancerGastroenterologyGeneral MedicineTransfectionFas receptorMolecular biologydigestive system diseasesErbB ReceptorsOxaliplatinmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureCancer researchbiology.proteinMyeloid Cell Leukemia Sequence 1 ProteinCamptothecinFluorouracilColorectal NeoplasmsWorld Journal of Gastroenterology
researchProduct

Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

2011

Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorou…

Organoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Blotting WesternFluorescent Antibody TechniqueAntineoplastic AgentsBiologyBioinformaticsReal-Time Polymerase Chain ReactionTransfectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineHeat shock proteinCell Line TumormedicineHumansImmunoprecipitationHSP110 Heat-Shock ProteinsneoplasmsCellular localizationComputingMilieux_MISCELLANEOUS030304 developmental biologyDNA Primers0303 health sciencesChemotherapyMicrosatellite instabilityGeneral MedicineTransfectionmedicine.diseasePrognosisdigestive system diseases3. Good healthOxaliplatinOxaliplatin030220 oncology & carcinogenesisCancer cellMutationCancer researchRegression AnalysisMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugPlasmids
researchProduct

Salmo trutta is more sensitive than Oncorhynchus mykiss to early-life stage exposure to retene

2021

Salmonids are known to be among the most sensitive fish to dioxin-like compounds (DLCs), but very little is known about the sensitivity of the brown trout (Salmo trutta), which has declined and is endangered in several countries of Europe and Western Asia. We investigated the sensitivity of brown trout larvae to a widespread dioxin-like PAH, retene (3.2 to 320 μg.L−1), compared to the larvae of a salmonid commonly used in toxicology studies, the rainbow trout (Oncorhynchus mykiss). Mortality, growth, cyp1a induction and the occurrence of deformities were measured after 15 days of exposure. Brown trout larvae showed a significantly higher mortality at 320 μg.L−1 compared to rainbow trout lar…

PAH-yhdisteetkuolleisuusendocrine systemanimal structuresPhysiologyanimal diseasesHealth Toxicology and MutagenesisZoologyBiologyToxicologydigestive systemBiochemistryReteneToxicology studiesBrown troutchemistry.chemical_compoundPAHstaimenSpecies SpecificitykirjolohiepämuodostumatAnimalshaitalliset aineetSalmoReteneLarvaDose-Response Relationship Drugurogenital systemCYP1AAhRSalmonidslohikalatGene Expression Regulation DevelopmentalWestern asiaCell BiologyGeneral MedicinePhenanthrenesbiology.organism_classificationEarly lifeekotoksikologiachemistryLarvaOncorhynchus mykissRNAEmbryotoxicityRainbow troutAryl Hydrocarbon HydroxylasesSalmonidaeWater Pollutants ChemicalComparative Biochemistry and Physiology Part C: Toxicology & Pharmacology
researchProduct

Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal a…

2017

Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells (UCOGC) is currently considered a morphologically and clinically distinct variant of pancreatic ductal adenocarcinoma (PDAC). In this study, we report clinical and pathological features of a series of 22 UCOGCs, including the whole exome sequencing of eight UCOGCs. We observed that 60% of the UCOGCs contained a well-defined epithelial component and that patients with pure UCOGC had a significantly better prognosis than did those with an UCOGC with an associated epithelial neoplasm. The genetic alterations in UCOGC are strikingly similar to those known to drive conventional PDAC, including activating mutations in the…

PDAC variants; Undifferentiated carcinoma with osteoclast-like giant cells; whole exome sequencingAged 80 and overMaleendocrine system diseasesCarcinomaUndifferentiated carcinoma with osteoclast-like giant cellsundifferentiated carcinoma with osteoclast-like giant cellOsteoclastsMiddle AgedImmunohistochemistrydigestive system diseasesArticleNeoplasm Proteinswhole exome sequencingPDAC variants; undifferentiated carcinoma with osteoclast-like giant cells; whole exome sequencing; Aged; Aged 80 and over; Carcinoma Pancreatic Ductal; Exome; Female; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Proteins; Osteoclasts; Pancreatic NeoplasmsPancreatic NeoplasmsPDAC variantsPancreatic DuctalMutation80 and overHumansExomeFemaleAgedCarcinoma Pancreatic Ductal
researchProduct

Biliary Pancreatitis: Endoscopic Diagnostic and Therapeutic Techniques

1987

Acute pancreatitis constitutes one of the most hazardous emergencies in clinical gastroenterology. Although the diagnosis “biliary pancreatitis” is often used in clinical practice for patients presenting with concrements in the biliary tree or impacted in the papillary orifice [17, 32], the common phrase “biliary pancreatitis” has not so far been exactly defined. Patients with cholecystolithiasis may be included in this group, as well as patients with dysfunction of the sphincter of Oddi. Some authors have reported that juxtapapillary diverticula increase the risk for development of biliary pancreatitis [28].

Pancreatic ductmedicine.medical_specialtybusiness.industryBile ductmedicine.diseasedigestive systemGastroenterologyClinical Practicemedicine.anatomical_structureInternal medicineSphincter of OddimedicineAcute cholecystitisAcute pancreatitisCommon bile duct stoneBiliary pancreatitisbusiness
researchProduct

Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients

2015

Background Multiple myeloma (MM) is a neoplastic disorder of plasma cells interesting mainly the elderly. MM remains an incurable disease, mostly because of the strong interplay between clonal plasma cells (cPCs) and bone marrow (BM) microenvironment. Multiparameter flow cytometry (MFC) allows the simultaneous study of the cPC immunophenotype and alterations involving other cells in BM, but rarely these data are interpreted as connected. One exception to this habit are previous studies about relationship between CD117 cPC positivity and hematopoietic progenitor cell (HPC) distribution in newly diagnosed patients. Thus we were interested in verifying the distribution of BM CD34+ HPCs in heal…

Pathologymedicine.medical_specialtyAgingImmunologyCD34CD117ImmunophenotypingCD117; Flow cytometry; Hematopoietic progenitor cell; MGUS; Multiple myeloma; Immunology; AgingMultiple myelomamedicineHematopoietic progenitor cellFlow cytometryMultiple myelomaSettore MED/04 - Patologia GeneralebiologyCD117business.industryResearchmedicine.diseasedigestive system diseasesAgeingmedicine.anatomical_structurebiology.proteinMGUSBone marrowAntibodybusinessProgressive diseaseMonoclonal gammopathy of undetermined significance
researchProduct